Reconstitute with 2ml of bacteriostatic water
or BMI 27 kg/m with at least one indicator of increased cardiovascular risk (e.g., coronary heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference), or another obesity-related medical condition (e.g., sleep apnea)
In Phase 2 trials, participants on the highest dose (12mg weekly) lost an average of 24.2% of their body weight over 48 weeks, results that surpass both semaglutide and tirzepatide at their respective trial endpoints
SPL UNCLASSIFIED SECTION Metabolism Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid, and amide hydrolysis
Kerksick, C., & Willoughby, D